Zobrazeno 1 - 10
of 160
pro vyhledávání: '"Georgia M Beasley"'
Autor:
Dirk Schadendorf, Gino K In, Mark R Middleton, Mohammed Milhem, Adel Samson, Bartosz Chmielowski, Michael K Wong, Robert S Coffin, Trisha M Wise-Draper, Eva Muñoz-Couselo, Joseph J Sacco, Georgia M Beasley, Judith Michels, Praveen K Bommareddy, Katy K Tsai, Jeannie W Hou, Alina Monteagudo, Tawnya Lynn Bowles, Ari M VanderWalde, Jason Alan Chesney, Fade Mahmoud, Walter Hong, Aaron Clack
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/4ff8ea73c0584af5a6764e1f92cc3eda
Autor:
Hong Zheng, Uzma Khan, Xiaofei Wang, Xiaoqing Yu, Georgia M Beasley, James Ronald, Jhanelle E Gray, Scott J Antonia, Steven Wolf, Neal E Ready, Bruna Pellini, Andreas N Saltos, Christy Arrowood, Ghassan El-Haddad, Tawee Tanvetyanon, Luiziane Guerra-Guevara, Lin Gu, Dana Foresman, Mark J Cantwell, Amer A Beg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/105d880a19504b1fae2902e604088ef5
Autor:
Daniel Landi, Annick Desjardins, Matthias Gromeier, Darell D Bigner, Smita K Nair, Michael C Brown, Georgia M Beasley, David M Ashley, Yuanfan Yang, Zachary P McKay, Dina M Randazzo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 4 (2023)
Background Antitumor mechanisms of CD4+ T cells remain crudely defined, and means to effectively harness CD4+ T-cell help for cancer immunotherapy are lacking. Pre-existing memory CD4+ T cells hold potential to be leveraged for this purpose. Moreover
Externí odkaz:
https://doaj.org/article/73dcacec3cd343d394456d6088d99ca1
Autor:
Matthias Gromeier, Darell D Bigner, Smita K Nair, David Boczkowski, Michael C Brown, Karenia Landa, Sin-Ho Jung, Georgia M Beasley, Norma E Farrow, Maria Angelica Selim, Rami N Al-Rohil, Aaron D Therien, Junheng Gao, Eda K Holl
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background We previously reported results from a phase 1 study testing intratumoral recombinant poliovirus, lerapolturev, in 12 melanoma patients. All 12 patients received anti-PD-1 systemic therapy before lerapolturev, and 11 of these 12 patients al
Externí odkaz:
https://doaj.org/article/04605eb95ab14089a2829c1d83ca4646
Autor:
Avani M. Kolla BPhil, Gerardo A. Vitiello MD, Erica B. Friedman MD, James Sun MD, Aishwarya Potdar MS, Hala Daou BS, Norma E. Farrow MD, Clara R. Farley MD, John T. Vetto MD, Dale Han MD, Marvi Tariq MD, Georgia M Beasley MD, Carlo M. Contreras MD, Michael Lowe MD, Jonathan S. Zager MD, Iman Osman MD, Russell S. Berman MD, Tracey N. Liebman MD, Jennifer A. Stein MD PhD, Ann Y. Lee MD
Publikováno v:
Cancer Control, Vol 28 (2021)
Background Acral lentiginous melanoma is associated with worse survival than other subtypes of melanoma. Understanding prognostic factors for survival and recurrence can help better inform follow-up care. Objectives To analyze the clinicopathologic f
Externí odkaz:
https://doaj.org/article/57f410acb38d4768a497f22089e561a6
Autor:
Matthias Gromeier, Darell D Bigner, Smita K Nair, Karenia Landa, Sin-Ho Jung, Georgia M Beasley, Norma E Farrow, Maria Angelica Selim, Carol Ann Wiggs, Andrea True Kelly, April KS Salama
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Background While programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists have improved the prognosis for many patients with melanoma, around 60% fail therapy. PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chime
Externí odkaz:
https://doaj.org/article/e28cb6ceb21645b987a84e695f9c4187
Publikováno v:
Frontiers in Bioscience-Landmark, Vol 27, Iss 2, p 063 (2022)
Malignant melanoma recurrence remains heterogeneous in presentation, ranging from locoregional disease (i.e., local recurrence, satellites, in transit disease) to distant dermal and visceral metastases. This diverse spectrum of disease requires a per
Externí odkaz:
https://doaj.org/article/400afd2ad09943fd8557831229ef1035
Autor:
Kristy K, Broman, Tasha M, Hughes, Brooke C, Bredbeck, James, Sun, Dennis, Kirichenko, Michael J, Carr, Avinash, Sharma, Edmund K, Bartlett, Amanda A G, Nijhuis, John F, Thompson, Tina J, Hieken, Lisa, Kottschade, Jennifer, Downs, David E, Gyorki, Emma, Stahlie, Alexander, van Akkooi, David W, Ollila, Kristin, O'shea, Yun, Song, Giorgos, Karakousis, Marc, Moncrieff, Jenny, Nobes, John, Vetto, Dale, Han, Meghan, Hotz, Jeffrey M, Farma, Jeremiah L, Deneve, Martin D, Fleming, Matthew, Perez, Kirsten, Baecher, Michael, Lowe, Roger Olofsson, Bagge, Jan, Mattsson, Ann Y, Lee, Russell S, Berman, Harvey, Chai, Hidde M, Kroon, Juri, Teras, Roland M, Teras, Norma E, Farrow, Georgia M, Beasley, Jane Yuet Ching, Hui, Lukas, Been, Schelto, Kruijff, Brandy, Sinco, Amod A, Sarnaik, Vernon K, Sondak, Jonathan S, Zager, Lesly A, Dossett
Publikováno v:
Annals of Surgery. 277(5):1106-1115
Objective: The aim of this study was to determine overall trends and center-level variation in utilization of completion lymph node dissection (CLND) and adjuvant systemic therapy for sentinel lymph node (SLN)-positive melanoma. Summary Background Da
Publikováno v:
Annals of Surgical Oncology. 30:2586-2589
Publikováno v:
Surgical Oncology Clinics of North America. 32:47-63